Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy

In this study we found similar attained dose level and patient outcomes, supporting a role for peg-GCSF with dose-adjusted EPOCH-R.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 14, 2017 Category: Hematology Authors: Prathima Reddy, Sandra Kanan, Andrew Cowan, Houston Warren, Brian Till, Mazyar Shadman, Ryan Cassaday, Oliver Press, Andrei Shustov, Ajay Gopal, Stephen D. Smith Tags: Original Study Source Type: research